Cannabis research is dangerously behind the reality of legalization, and the field needs new study designs

63% of the US population has access to medicinal cannabis markets offering increasingly diverse and potent products. The scientific literature does not adequately inform public policy, medical decision making, or harm reduction approaches. Key barriers include federal scheduling, DEA licensing, and limited approved research cannabis.

Review examining the state of cannabis research for commonly treated conditions, barriers to research progress, and proposed innovative research designs to address knowledge gaps.

Millions of people are using cannabis products with minimal scientific guidance. The regulatory barriers that prevent proper research create an information vacuum filled by marketing claims and anecdotes, which is harmful to both users and non-users.

The cannabis knowledge gap is not just a scientific problem but a public health emergency. People are making health decisions daily about a product whose effects are largely unstudied using modern methods. The field needs the same urgency applied to other public health crises.

Focuses on US regulatory context, though similar barriers exist in other countries. Proposed innovative designs have not been fully validated. Does not provide a timeline for when the knowledge gap might close.